argenx (NASDAQ:ARGX) had its price objective boosted by Wedbush from $144.00 to $170.00 in a report released on Friday, BenzingaRatingsTable reports. The brokerage currently has an outperform rating on the stock.
Other equities research analysts have also recently issued research reports about the stock. Robert W. Baird started coverage on shares of argenx in a research report on Thursday, June 27th. They set an outperform rating and a $170.00 price objective for the company. Zacks Investment Research cut shares of argenx from a buy rating to a hold rating in a research report on Tuesday, July 16th. ValuEngine cut shares of argenx from a buy rating to a hold rating in a research report on Thursday, August 1st. Piper Jaffray Companies upped their price objective on shares of argenx from $161.00 to $182.00 and gave the stock an overweight rating in a research report on Thursday, May 23rd. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $154.00 price objective on shares of argenx in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $152.27.
ARGX opened at $133.00 on Friday. argenx has a twelve month low of $63.81 and a twelve month high of $150.92. The business’s 50-day moving average price is $141.39. The company has a market capitalization of $4.59 billion, a PE ratio of -56.60 and a beta of 1.18.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Article: How is diluted EPS different from basic EPS?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.